Nasdaq · Healthcare
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
As-reported financials and recent SEC filings for IOVANCE BIOTHERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$263.5M
Net income
$-391.0M
Net margin
-148.4%
Diluted EPS
$-1.09
ROE
-56.0%
P/E (TTM)
—
Market cap
$1.90B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | — | — |
| Gross profit | $90.3M | $70.8M | $156,000 | — | — |
| Operating income | $-403.4M | $-395.3M | $-460.6M | $-398.9M | $-342.7M |
| Net income | $-391.0M | $-372.2M | $-444.0M | $-395.9M | $-342.3M |
| Diluted EPS | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →S-82026-06-18
View on EDGAR →S-82026-06-18
View on EDGAR →S-3ASR2026-06-18
View on EDGAR →Go deeper on IOVA
Search IOVANCE BIOTHERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.